Treatment with Hizentra in patients with primary and secondary immunodeficiencies: a real-life, non-interventional trial.

BMC Immunol · 2016 · PMC5041334 · PMID 27687879

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

likely to be significantno p-value reported

Once again the differences in treatment populations are likely to be significant contributors to discrepancies between studies as patients with secondary immunodeficiencies are likely to be older and to have more comorbidities.

also in 1,824 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.